조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2024년07월
CAR T-cell Therapy Market – Global Forecast to 2029
CAR-T 세포 치료 시장 – 제품(아베쿠마, 브레얀지, 칼비티, 예수카르타, 테카르투스, 킴리아), 표적 항원(CD19, BCMA), 적응증(다발성 골수종, 백혈병, 림프종), 인구통계(성인, 소아), 최종 사용자 및 시장 규모, 점유율 및 추세, 지역별 – 2029년까지의 세계 예측
CAR T-cell Therapy Market Size, Share & Trends by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region – Global Forecast to 2029
| 페이지 수 | 266 |
| 도표 수 | 329 |
| 가격 | |
| Single User License | USD 4,950 |
| Multi User License | USD 6,650 |
| Corporate License | USD 8,150 |
| Enterprise License | USD 10.000 |
| 구성 | 영문조사보고서 |
Report Overview
The global CAR T-cell therapy market is estimated to reach USD 29.0 Billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period of 2024 to 2029.
세계 CAR-T 세포 치료 시장은 2024년부터 2029년까지의 예측 기간 동안 39.6%의 CAGR로 2024년 55억 달러에서 2029년까지 290억 달러에 이를 것으로 추정된다.
Market growth is driven by the rise in the global cancer prevalence. Technological advancements in CAR T-cell therapies and rising therapy development investment and funding is likely to propel the market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are some of the major factors expected to restrain the market growth during the forecast period.
“Yescarta segment accounted for the highest share of 2023.”
Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment held the largest market share in 2023. Market growth is attributed to high response rates and durable remissions of Yescarta in treating relapsed/refractory cancers leading to an increase in therapy adoption.
“The Hospitals End User segment held the dominant share in the CAR T-cell therapy market.”
Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period. Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment protocols. This trend is boosting demand for CAR T-cell treatments as more hospitals embrace these therapies. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborations with pharmaceutical companies, hospitals contribute to expanding the evidence base and accelerating regulatory approvals, which in turn stimulates market growth.
“Asia Pacific region estimated to show fastest growth rate.”
The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. During the forecast period, Asia Pacific region is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in the Asia Pacific market. In addition, increasing collaborations between hospitals, universities, and industries in Chinaare expected to provide lucrative market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific’s progress in developing and validating CAR T-cell treatments, positioning the region as a key player in advancing therapeutic outcomes in oncology in CAR T-cell therapy.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70%, and Demand Side – 30%
- By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%
List of Companies Profiled in the Report:
- Bristol-Myers Squibb Company (US)
- Gilead Sciences Inc. (US)
- Novartis AG (Switzerland)
- Johnson & Johnson (US)
- CARsgen Therapeutics Holdings Limited (China)
- IASO Biotherapeutics (China)
- JW (Cayman) Therapeutics Co. Ltd (China)
- ImmunoAct (India)
- CRISPR Therapeutics (Switzerland)
- Autolus Therapeutics (UK)
- Allogene Therapeutics (US)
- Cartesian Therapeutics Inc. (US)
- Guangzhou Bio-gene Technology Co. Ltd (China)
- Wugen (US).
Research Coverage:
This report provides a detailed picture of the CAR T-cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as product, target, demographic, indications, end-users and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (technological advancements in CAR T-cell therapies, growing cancer prevalence, and rising investment and funding for therapy development), restraints (high therapy costs and adverse effects), opportunities (expansion into solid tumors and collaborations and partnerships) and challenges (patient recruitment for trials and reimbursement issues) are influencing the growth of CAR T-cell therapy market.
- Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the CAR T-cell therapy market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.
Table of Contents
1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 MARKET SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 REGIONS COVERED 27
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 28
1.4 STAKEHOLDERS 28
1.5 RECESSION IMPACT 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.1.1 SECONDARY DATA 30
2.1.2 PRIMARY DATA 31
2.1.3 BREAKDOWN OF PRIMARIES 31
2.2 MARKET SIZE ESTIMATION 32
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 35
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION 36
2.3 GROWTH RATE ASSUMPTIONS 37
2.3.1 CAGR PROJECTIONS 37
2.3.2 IMPACT OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 38
2.4 VOLUME ESTIMATION 38
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 39
2.6 RESEARCH LIMITATIONS 40
2.7 STUDY ASSUMPTIONS 40
2.8 RISK ANALYSIS 41
2.9 RECESSION IMPACT ANALYSIS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 46
4.1 CAR T-CELL THERAPY MARKET OVERVIEW 46
4.2 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT AND COUNTRY (2023) 47
4.3 CAR T-CELL THERAPY MARKET SHARE, BY PRODUCT 48
4.4 CAR T-CELL THERAPY MARKET, BY END USER 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 50
5.2.1.1 Growing cancer prevalence 50
5.2.1.2 Technological advancements in CAR T-cell therapies 50
5.2.1.3 Rising investment and funding for therapy development 51
5.2.2 RESTRAINTS 52
5.2.2.1 High therapy costs 52
5.2.2.2 Adverse effects 53
5.2.3 OPPORTUNITIES 54
5.2.3.1 Expansion into solid tumors 54
5.2.3.2 Collaborations and partnerships 55
5.2.4 CHALLENGES 57
5.2.4.1 Patient recruitment for trials 57
5.2.4.2 Reimbursement issues 57
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 59
5.4 VALUE CHAIN ANALYSIS 60
5.5 ECOSYSTEM ANALYSIS 62
5.5.1 PRODUCTS 62
5.5.2 END USERS 63
5.5.3 REGULATORY BODIES 64
5.6 TECHNOLOGY ANALYSIS 65
5.6.1 KEY TECHNOLOGIES 65
5.6.1.1 CAR DESIGN AND OPTIMIZATION 65
5.6.1.2 VIRAL VECTOR TECHNOLOGY 65
5.6.1.3 CELL CULTURE AND EXPANSION TECHNIQUES 65
5.6.2 COMPLIMENTARY TECHNOLOGIES 66
5.6.2.1 GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING) 66
5.6.3 ADJACENT TECHNOLOGIES 67
5.6.3.1 MONITORING AND IMAGING TECHNOLOGIES 67
5.7 PATENT ANALYSIS 67
5.7.1 METHODOLOGY 68
5.7.2 NUMBER OF PATENTS FILED 68
5.7.3 INNOVATION AND PATENT APPLICATIONS 68
5.7.4 TOP APPLICANTS 69
5.8 PRICING ANALYSIS 71
5.8.1 AVERAGE SELLING PRICE, BY TYPE 72
5.8.2 AVERAGE SELLING PRICE, BY REGION 73
5.8.3 AVERAGE SELLING PRICE TREND, BY PRODUCT 74
5.9 KEY CONFERENCES & EVENTS, 2024–2O25 75
5.10 REGULATORY LANDSCAPE 76
5.10.1 REGULATORY SCENARIO 76
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
5.11 INVESTMENT & FUNDING SCENARIO 80
5.12 PORTER’S FIVE FORCES ANALYSIS 81
5.12.1 INTENSITY OF COMPETITIVE RIVALRY 82
5.12.2 BARGAINING POWER OF SUPPLIERS 82
5.12.3 BARGAINING POWER OF BUYERS 82
5.12.4 THREAT OF SUBSTITUTES 82
5.12.5 THREAT OF NEW ENTRANTS 82
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 83
5.13.1 KEY BUYING CRITERIA 84
6 CAR T-CELL THERAPY MARKET, BY PRODUCT 86
6.1 INTRODUCTION 87
6.2 YESCARTA 88
6.2.1 INCREASING REACH TO DRIVE MARKET 88
6.3 KYMRIAH 90
6.3.1 APPROVAL FOR PEDIATRIC USE TO SUPPORT MARKET GROWTH 90
6.4 CARVYKTI 92
6.4.1 WIDESPREAD REACH TO ENSURE MARKET GROWTH 92
6.5 ABECMA 95
6.5.1 RISING RESEARCH FOR ALTERNATIVE INDICATIONS TO DRIVE MARKET 95
6.6 TECARTUS 97
6.6.1 GROWING FOCUS ON PATIENT-CENTRIC REIMBURSEMENT
TO PROPEL MARKET 97
6.7 BREYANZI 99
6.7.1 MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH 99
6.8 OTHER PRODUCTS 102
7 CAR T-CELL THERAPY MARKET, BY TARGET 106
7.1 INTRODUCTION 107
7.2 CD19 107
7.2.1 RISING INDICATIONS IN PIPELINE TO DRIVE MARKET 107
7.3 BCMA 110
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPY TO PROPEL MARKET GROWTH 110
7.4 OTHER TARGETS 113
8 CAR T-CELL THERAPY MARKET, BY INDICATION 117
8.1 INTRODUCTION 118
8.2 MULTIPLE MYELOMA 118
8.2.1 RISING INCIDENCE OF MULTIPLE MYELOMA TO DRIVE MARKET 118
8.3 B-CELL LYMPHOMA 121
8.3.1 RISING PREVALENCE TO PROPEL MARKET GROWTH 121
8.4 ACUTE LYMPHOBLASTIC LEUKEMIA 123
8.4.1 FOCUS ON AFFORDABLE CAR T-CELL THERAPIES TO DRIVE MARKET 123
8.5 OTHER INDICATIONS 126
9 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC 130
9.1 INTRODUCTION 131
9.2 ADULTS 131
9.2.1 INCREASING NUMBER OF LYMPHOMAS TO DRIVE MARKET 131
9.3 PEDIATRICS 133
9.3.1 RISING PREVALENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH 133
10 CAR T-CELL THERAPY MARKET, BY END USER 137
10.1 INTRODUCTION 138
10.2 HOSPITALS 138
10.2.1 GROWING PREVALENCE OF CANCER TO DRIVE MARKET 138
10.3 SPECIALTY CENTERS 140
10.3.1 GROWING RESEARCH COLLABORATIONS TO PROPEL MARKET 140
10.4 LONG-TERM CARE FACILITIES 143
10.4.1 GROWING CASES OF CHRONIC DISORDERS TO DRIVE MARKET 143
11 CAR T-CELL THERAPY MARKET, BY REGION 146
11.1 INTRODUCTION 147
11.2 NORTH AMERICA 147
11.2.1 NORTH AMERICA: RECESSION IMPACT 147
11.2.2 US 151
11.2.2.1 Rising R&D activities for CAR T-cell therapies to drive market 151
11.2.3 CANADA 154
11.2.3.1 Government initiatives for regenerative medicine research to drive market 154
11.3 EUROPE 156
11.3.1 EUROPE: RECESSION IMPACT 156
11.3.2 GERMANY 159
11.3.2.1 Rising focus on clinical research to drive market 159
11.3.3 UK 162
11.3.3.1 Rising technological advancements in automation to drive market 162
11.3.4 FRANCE 164
11.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand 164
11.3.5 ITALY 167
11.3.5.1 Growth in biotech sector to drive market 167
11.3.6 SPAIN 169
11.3.6.1 Rising focus on cell therapies to support market growth 169
11.3.7 REST OF EUROPE 171
11.4 ASIA PACIFIC 174
11.4.1 ASIA PACIFIC: RECESSION IMPACT 174
11.4.2 CHINA 178
11.4.2.1 Rising number of CAR T-cell clinical trials to support market growth 178
11.4.3 JAPAN 181
11.4.3.1 Increasing product approvals to drive market 181
11.4.4 INDIA 183
11.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand 183
11.4.5 AUSTRALIA 185
11.4.5.1 Robust infrastructure for clinical trials and well-developed healthcare sector to drive market 185
11.4.6 SOUTH KOREA 188
11.4.6.1 Rising growth in biopharmaceutical industry to drive market 188
11.4.7 REST OF ASIA PACIFIC 190
11.5 LATIN AMERICA 192
11.5.1 LATIN AMERICA: RECESSION IMPACT 192
11.5.2 BRAZIL 195
11.5.2.1 High expenditure on healthcare to support market growth 195
11.5.3 REST OF LATIN AMERICA 198
11.6 MIDDLE EAST & AFRICA 200
11.6.1 MEA TO GROW AT SLOWER PACE DURING FORECAST PERIOD 200
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 201
12 COMPETITIVE LANDSCAPE 204
12.1 OVERVIEW 204
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 204
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL
THERAPY MARKET 205
12.3 REVENUE ANALYSIS 206
12.4 MARKET SHARE ANALYSIS 207
12.4.1 RANKING OF KEY MARKET PLAYERS 209
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 209
12.5.1 STARS 209
12.5.2 EMERGING LEADERS 210
12.5.3 PERVASIVE PLAYERS 210
12.5.4 PARTICIPANTS 210
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 211
12.5.5.1 Company footprint 211
12.5.5.2 Product footprint 211
12.5.5.3 Target footprint 212
12.5.5.4 Indication footprint 212
12.5.5.5 Region footprint 213
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 213
12.6.1 PROGRESSIVE COMPANIES 213
12.6.2 RESPONSIVE COMPANIES 213
12.6.3 DYNAMIC COMPANIES 214
12.6.4 STARTING BLOCKS 214
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 215
12.7 VALUATION & FINANCIAL METRICS 216
12.7.1 FINANCIAL METRICS 216
12.7.2 COMPANY VALUATION 216
12.8 BRAND/PRODUCT COMPARISON 217
12.9 COMPETITIVE SCENARIO 218
12.9.1 PRODUCT LAUNCHES & APPROVALS 218
12.9.2 DEALS 219
12.9.3 EXPANSIONS 220
12.9.4 OTHER DEVELOPMENTS 220
13 COMPANY PROFILES 221
13.1 KEY PLAYERS 221
13.1.1 BRISTOL-MYERS SQUIBB COMPANY 221
13.1.1.1 Business overview 221
13.1.1.2 Products offered 223
13.1.1.3 Recent developments 223
13.1.1.3.1 Product approvals 223
13.1.1.3.2 Deals 225
13.1.1.4 MnM view 225
13.1.1.4.1 Key strengths 225
13.1.1.4.2 Strategic choices 225
13.1.1.4.3 Weaknesses & competitive threats 225
13.1.2 GILEAD SCIENCES, INC. 226
13.1.2.1 Business overview 226
13.1.2.2 Products offered 228
13.1.2.3 Recent developments 229
13.1.2.3.1 Product approvals 229
13.1.2.3.2 Deals 229
13.1.2.3.3 Other developments 230
13.1.2.4 MnM view 230
13.1.2.4.1 Key strengths 230
13.1.2.4.2 Strategic choices 231
13.1.2.4.3 Weaknesses & competitive threats 231
13.1.3 NOVARTIS AG 232
13.1.3.1 Business overview 232
13.1.3.2 Products offered 234
13.1.3.3 Recent developments 235
13.1.3.3.1 Product launches & approvals 235
13.1.3.3.2 Expansions 235
13.1.3.3.3 Other developments 236
13.1.3.4 MnM view 236
13.1.3.4.1 Key strengths 236
13.1.3.4.2 Strategic choices 236
13.1.3.4.3 Weaknesses and competitive threats 236
13.1.4 JOHNSON & JOHNSON 237
13.1.4.1 Business overview 237
13.1.4.2 Products offered 238
13.1.4.3 Recent developments 239
13.1.4.3.1 Product approvals 239
13.1.4.3.2 Deals 239
13.1.5 JW (CAYMAN) THERAPEUTICS CO. LTD. 240
13.1.5.1 Business overview 240
13.1.5.2 Products offered 241
13.1.5.3 Recent developments 241
13.1.5.3.1 Product approvals 241
13.1.5.3.2 Deals 242
13.1.6 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT) 243
13.1.6.1 Business overview 243
13.1.6.2 Products offered 243
13.1.6.3 Recent developments 244
13.1.6.3.1 Deals 244
13.1.6.3.2 Other developments 245
13.1.7 CARSGEN THERAPEUTICS HOLDINGS LIMITED 246
13.1.7.1 Business overview 246
13.1.7.2 Products offered 247
13.1.7.3 Recent developments 247
13.1.7.3.1 Product approvals 247
13.1.7.3.2 Deals 248
13.1.7.3.3 Expansions 249
13.1.8 IASO BIOTHERAPEUTICS 250
13.1.8.1 Business overview 250
13.1.8.2 Products offered 250
13.1.8.3 Recent developments 251
13.1.8.3.1 Product approvals 251
13.1.8.3.2 Deals 251
13.2 OTHER PLAYERS 252
13.2.1 GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD (HEDY GROUP CO., LTD.) 252
13.2.2 CARTESIAN THERAPEUTICS, INC. 253
13.2.3 AUTOLUS THERAPEUTICS 254
13.2.4 ALLOGENE THERAPEUTICS 255
13.2.5 CRISPR THERAPEUTICS 256
13.2.6 WUGEN 257
14 APPENDIX 258
14.1 DISCUSSION GUIDE 258
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 262
14.3 CUSTOMIZATION OPTIONS 264
14.4 RELATED REPORTS 264
14.5 AUTHOR DETAILS 265
LIST OF TABLES
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 38
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2023–2029 (% GROWTH) 41
TABLE 3 ADVERSE EFFECTS ASSOCIATED WITH CAR T-CELL THERAPY 53
TABLE 4 KEY PRODUCT PROVIDERS IN CAR T-CELL THERAPY MARKET 63
TABLE 5 KEY END USERS IN CAR T-CELL THERAPY MARKET 63
TABLE 6 KEY REGULATORY BODIES IN CAR T-CELL THERAPY MARKET 64
TABLE 7 NUMBER OF PATENTS FILED IN CAR T-CELL THERAPY MARKET, BY DOCUMENT TYPE, 2014–2024 68
TABLE 8 TOP 12 PATENT OWNERS IN CAR T-CELL THERAPY MARKET, 2014–2024 70
TABLE 9 DETAILED ANALYSIS OF KEY PATENTS IN CAR T-CELL THERAPY MARKET 70
TABLE 10 AVERAGE SELLING PRICE FOR LEADING CAR T-CELL THERAPEUTIC DRUGS 72
TABLE 11 AVERAGE SELLING PRICE FOR MAJOR CAR T-CELL THERAPEUTIC DRUGS,
BY REGION 73
TABLE 12 INDICATIVE PRICING ANALYSIS FOR CAR T-CELL THERAPY, BY PRODUCT,
2021–2023 74
TABLE 13 KEY CONFERENCES & EVENTS, JUNE 2024–DECEMBER 2025 75
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 19 CAR T-CELL THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 81
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 83
TABLE 21 KEY BUYING CRITERIA FOR PRODUCTS 84
TABLE 22 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 87
TABLE 23 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (UNITS) 87
TABLE 24 YESCARTA MARKET, BY REGION, 2022–2029 (USD MILLION) 88
TABLE 25 NORTH AMERICA: YESCARTA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 89
TABLE 26 EUROPE: YESCARTA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 89
TABLE 27 ASIA PACIFIC: YESCARTA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 89
TABLE 28 LATIN AMERICA: YESCARTA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 90
TABLE 29 KYMRIAH MARKET, BY REGION, 2022–2029 (USD MILLION) 91
TABLE 30 NORTH AMERICA: KYMRIAH MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 31 EUROPE: KYMRIAH MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 32 ASIA PACIFIC: KYMRIAH MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 33 LATIN AMERICA: KYMRIAH MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 34 CARVYKTI MARKET, BY REGION, 2022–2029 (USD MILLION) 93
TABLE 35 NORTH AMERICA: CARVYKTI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 93
TABLE 36 EUROPE: CARVYKTI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 37 ASIA PACIFIC: CARVYKTI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 38 LATIN AMERICA: CARVYKTI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 39 ABECMA MARKET, BY REGION, 2022–2029 (USD MILLION) 96
TABLE 40 NORTH AMERICA: ABECMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 96
TABLE 41 EUROPE: ABECMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 96
TABLE 42 ASIA PACIFIC: ABECMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 43 LATIN AMERICA: ABECMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 44 TECARTUS MARKET, BY REGION, 2022–2029 (USD MILLION) 98
TABLE 45 NORTH AMERICA: TECARTUS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 46 EUROPE: TECARTUS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 47 ASIA PACIFIC: TECARTUS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 48 LATIN AMERICA: TECARTUS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 49 BREYANZI MARKET, BY REGION, 2022–2029 (USD MILLION) 100
TABLE 50 NORTH AMERICA: BREYANZI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 51 EUROPE: BREYANZI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 52 ASIA PACIFIC: BREYANZI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 53 LATIN AMERICA: BREYANZI MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 54 OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY REGION,
2022–2029 (USD MILLION) 103
TABLE 55 NORTH AMERICA: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 56 EUROPE: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 57 ASIA PACIFIC: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 58 LATIN AMERICA: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 59 CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 107
TABLE 60 COMMERCIALLY AVAILABLE CD19 ANTIGEN-TARGETING CAR T-CELL THERAPIES 108
TABLE 61 CD19-TARGETING CAR T-CELL THERAPY MARKET, BY REGION,
2022–2029 (USD MILLION) 108
TABLE 62 NORTH AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 63 EUROPE: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 109
TABLE 64 ASIA PACIFIC: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 65 LATIN AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 66 COMMERCIALLY AVAILABLE BCMA ANTIGEN-TARGETING CAR T-CELL THERAPIES 111
TABLE 67 BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY REGION,
2022–2029 (USD MILLION) 111
TABLE 68 NORTH AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 69 EUROPE: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 112
TABLE 70 ASIA PACIFIC: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 71 LATIN AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 72 OTHER CAR T-CELL THERAPY TARGETS MARKET, BY REGION,
2022–2029 (USD MILLION) 114
TABLE 73 NORTH AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 74 EUROPE: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 115
TABLE 75 ASIA PACIFIC: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 76 LATIN AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 77 CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 118
TABLE 78 MULTIPLE MYELOMA, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 79 NORTH AMERICA: MULTIPLE MYELOMA MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 119
TABLE 80 EUROPE: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 81 ASIA PACIFIC: MULTIPLE MYELOMA MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 120
TABLE 82 LATIN AMERICA: MULTIPLE MYELOMA MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 120
TABLE 83 CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY REGION,
2022–2029 (USD MILLION) 121
TABLE 84 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA,
BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 85 EUROPE: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 86 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA,
BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 87 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA,
BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 88 CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA,
BY REGION, 2022–2029 (USD MILLION) 124
TABLE 89 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 90 EUROPE: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 91 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 92 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 93 CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY REGION,
2022–2029 (USD MILLION) 127
TABLE 94 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 95 EUROPE: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 96 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 97 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 98 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION) 131
TABLE 99 CAR T-CELL THERAPY MARKET FOR ADULTS, BY REGION,
2022–2029 (USD MILLION) 132
TABLE 100 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS,
BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 101 EUROPE: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY,
2022–2029 (USD MILLION) 132
TABLE 102 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 103 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 104 CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY REGION,
2022–2029 (USD MILLION) 134
TABLE 105 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 106 EUROPE: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY,
2022–2029 (USD MILLION) 135
TABLE 107 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 108 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 109 CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 138
TABLE 110 CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION,
2022–2029 (USD MILLION) 139
TABLE 111 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 112 EUROPE: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2022–2029 (USD MILLION) 139
TABLE 113 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 114 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 115 CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION,
2022–2029 (USD MILLION) 141
TABLE 116 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS,
BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 117 EUROPE: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 118 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS,
BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 119 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS,
BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 120 CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 121 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 122 EUROPE: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES,
BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 123 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES,
BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 124 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 125 CAR T-CELL THERAPY MARKET, BY REGION, 2022–2029 (USD MILLION) 147
TABLE 126 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 149
TABLE 127 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 149
TABLE 128 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 150
TABLE 129 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 150
TABLE 130 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 151
TABLE 131 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 151
TABLE 132 US: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 152
TABLE 133 US: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 152
TABLE 134 US: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 153
TABLE 135 US: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 153
TABLE 136 US: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 153
TABLE 137 CANADA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 154
TABLE 138 CANADA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 154
TABLE 139 CANADA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2
022–2029 (USD MILLION) 155
TABLE 140 CANADA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 155
TABLE 141 CANADA: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 155
TABLE 142 EUROPE: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 143 EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 157
TABLE 144 EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 158
TABLE 145 EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2
022–2029 (USD MILLION) 158
TABLE 146 EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 158
TABLE 147 EUROPE: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 159
TABLE 148 GERMANY: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 160
TABLE 149 GERMANY: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 160
TABLE 150 GERMANY: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 161
TABLE 151 GERMANY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 161
TABLE 152 GERMANY: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 161
TABLE 153 UK: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 162
TABLE 154 UK: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 163
TABLE 155 UK: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 163
TABLE 156 UK: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 163
TABLE 157 UK: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 164
TABLE 158 FRANCE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 165
TABLE 159 FRANCE: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 165
TABLE 160 FRANCE: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 166
TABLE 161 FRANCE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 166
TABLE 162 FRANCE: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 166
TABLE 163 ITALY: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 167
TABLE 164 ITALY: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 168
TABLE 165 ITALY: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 168
TABLE 166 ITALY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 168
TABLE 167 ITALY: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 169
TABLE 168 SPAIN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 169
TABLE 169 SPAIN: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 170
TABLE 170 SPAIN: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 170
TABLE 171 SPAIN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 170
TABLE 172 SPAIN: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 171
TABLE 173 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 172
TABLE 174 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 172
TABLE 175 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 173
TABLE 176 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 173
TABLE 177 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 173
TABLE 178 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 176
TABLE 179 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 176
TABLE 180 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 177
TABLE 181 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 177
TABLE 182 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 178
TABLE 183 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 178
TABLE 184 CHINA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 179
TABLE 185 CHINA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 179
TABLE 186 CHINA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 180
TABLE 187 CHINA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 180
TABLE 188 CHINA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 180
TABLE 189 JAPAN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 181
TABLE 190 JAPAN: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 182
TABLE 191 JAPAN: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 182
TABLE 192 JAPAN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 182
TABLE 193 JAPAN: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 183
TABLE 194 INDIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 183
TABLE 195 INDIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 184
TABLE 196 INDIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION) 184
TABLE 197 INDIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 184
TABLE 198 INDIA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 185
TABLE 199 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 186
TABLE 200 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 186
TABLE 201 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 187
TABLE 202 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 187
TABLE 203 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 187
TABLE 204 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 188
TABLE 205 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 189
TABLE 206 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 189
TABLE 207 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 189
TABLE 208 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 190
TABLE 209 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 190
TABLE 210 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 191
TABLE 211 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 191
TABLE 212 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 191
TABLE 213 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 192
TABLE 214 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 193
TABLE 215 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 193
TABLE 216 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 194
TABLE 217 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 194
TABLE 218 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 194
TABLE 219 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 195
TABLE 220 BRAZIL: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 196
TABLE 221 BRAZIL: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION) 196
TABLE 222 BRAZIL: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 197
TABLE 223 BRAZIL: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC,
2022–2029 (USD MILLION) 197
TABLE 224 BRAZIL: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION) 197
TABLE 225 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 198
TABLE 226 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 199
TABLE 227 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 199
TABLE 228 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION) 199
TABLE 229 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 200
TABLE 230 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 201
TABLE 231 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY TARGET,
2022–2029 (USD MILLION) 202
TABLE 232 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY INDICATION,
2022–2029 (USD MILLION) 202
TABLE 233 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION) 202
TABLE 234 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY END USER,
2022–2029 (USD MILLION) 203
TABLE 235 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 205
TABLE 236 CAR T-CELL THERAPY MARKET: DEGREE OF COMPETITION 208
TABLE 237 CAR T-CELL THERAPY MARKET: PRODUCT FOOTPRINT 211
TABLE 238 CAR T-CELL THERAPY MARKET: TARGET FOOTPRINT 212
TABLE 239 CAR T-CELL THERAPY MARKET: INDICATION FOOTPRINT 212
TABLE 240 CAR T-CELL THERAPY MARKET: REGION FOOTPRINT 213
TABLE 241 CAR T-CELL THERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 215
TABLE 242 CAR T-CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 215
TABLE 243 CAR T-CELL THERAPY MARKET: PRODUCT LAUNCHES &
APPROVALS, JANUARY 2021–MARCH 2024 218
TABLE 244 CAR T-CELL THERAPY MARKET: DEALS, JANUARY 2021–MARCH 2024 219
TABLE 245 CAR T-CELL THERAPY MARKET: EXPANSIONS, JANUARY 2021–MARCH 2024 220
TABLE 246 CAR T-CELL THERAPY MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–MARCH 2024 220
TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 221
TABLE 248 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 223
TABLE 249 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS,
JANUARY 2021–MAY 2024 223
TABLE 250 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021–MAY 2024 225
TABLE 251 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 226
TABLE 252 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 228
TABLE 253 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024 229
TABLE 254 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021–MAY 2024 229
TABLE 255 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 230
TABLE 256 NOVARTIS AG: COMPANY OVERVIEW 232
TABLE 257 NOVARTIS AG: PRODUCTS OFFERED 234
TABLE 258 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−MAY 2024 235
TABLE 259 NOVARTIS AG: EXPANSIONS, JANUARY 2021−MAY 2024 235
TABLE 260 NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2021−MAY 2024 236
TABLE 261 JOHNSON & JOHNSON: COMPANY OVERVIEW 237
TABLE 262 JOHNSON & JOHNSON: PRODUCTS OFFERED 238
TABLE 263 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 239
TABLE 264 JOHNSON & JOHNSON: DEALS, JANUARY 2021−MAY 2024 239
TABLE 265 JW (CAYMAN) THERAPEUTICS CO. LTD.: COMPANY OVERVIEW 240
TABLE 266 JW (CAYMAN) THERAPEUTICS CO. LTD.: PRODUCTS OFFERED 241
TABLE 267 JW (CAYMAN) THERAPEUTICS CO. LTD.: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 241
TABLE 268 JW (CAYMAN) THERAPEUTICS CO. LTD.: DEALS, JANUARY 2021−MAY 2024 242
TABLE 269 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: COMPANY OVERVIEW 243
TABLE 270 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: PRODUCTS OFFERED 243
TABLE 271 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: DEALS,
JANUARY 2021−MAY 2024 244
TABLE 272 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 245
TABLE 273 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW 246
TABLE 274 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED 247
TABLE 275 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS,
JANUARY 2021−MAY 2024 247
TABLE 276 CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS, JANUARY 2021−MAY 2024 248
TABLE 277 CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS,
JANUARY 2021−MAY 2024 249
TABLE 278 IASO BIOTHERAPEUTICS: COMPANY OVERVIEW 250
TABLE 279 IASO BIOTHERAPEUTICS: PRODUCTS OFFERED 250
TABLE 280 IASO BIOTHERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 251
TABLE 281 IASO BIOTHERAPEUTICS: DEALS, JANUARY 2021−MAY 2024 251
LIST OF FIGURES
FIGURE 1 CAR T-CELL THERAPY MARKET SEGMENTATION 26
FIGURE 2 CAR T-CELL THERAPY MARKET: REGIONAL SEGMENTATION 27
FIGURE 3 RESEARCH DESIGN 29
FIGURE 4 BREAKDOWN OF PRIMARIES: CAR T-CELL THERAPY MARKET 31
FIGURE 5 CAR T-CELL THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 32
FIGURE 6 CAR T-CELL THERAPY MARKET SIZE ESTIMATION
(PRODUCT-BASED ANALYSIS), 2023 33
FIGURE 7 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2023 34
FIGURE 8 ILLUSTRATIVE EXAMPLE OF GILEAD SCIENCES, INC.:
REVENUE SHARE ANALYSIS (2023) 34
FIGURE 9 MARKET VALIDATION FROM PRIMARY SOURCES 35
FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 36
FIGURE 11 CAR T-CELL THERAPY MARKET: CAGR PROJECTIONS, 2024–2029 37
FIGURE 12 DATA TRIANGULATION METHODOLOGY 39
FIGURE 13 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024 VS 2029 (USD MILLION) 42
FIGURE 14 CAR T-CELL THERAPY MARKET, BY TARGET, 2024 VS. 2029 (USD MILLION) 43
FIGURE 15 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024 VS. 2029 (USD MILLION) 43
FIGURE 16 CAR T-CELL THERAPY MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION) 44
FIGURE 17 CAR T-CELL THERAPY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 44
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF CAR T-CELL THERAPY MARKET 45
FIGURE 19 GROWING PREVALENCE OF CANCER TO DRIVE MARKET 46
FIGURE 20 US AND YESCARTA COMMANDED LARGEST SHARE IN NORTH AMERICAN CAR T-CELL THERAPY MARKET IN 2023 47
FIGURE 21 YESCARTA HELD HIGHEST GLOBAL MARKET SHARE IN 2023 48
FIGURE 22 HOSPITALS SEGMENT TO GROW AT HIGHEST CAGR DURING STUDY PERIOD 48
FIGURE 23 CAR T-CELL THERAPY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 49
FIGURE 24 REVENUE SHIFT IN CAR T-CELL THERAPY MARKET 59
FIGURE 25 VALUE CHAIN ANALYSIS: CAR T-CELL THERAPY PRODUCTS 60
FIGURE 26 CAR T-CELL THERAPY MARKET: ECOSYSTEM 62
FIGURE 27 TOTAL NUMBER OF PATENTS GRANTED IN CAR T-CELL THERAPY MARKET,
2014–2023 68
FIGURE 28 TOP 13 PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024 69
FIGURE 29 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014–2024 69
FIGURE 30 CAR T-CELL THERAPY MARKET 81
FIGURE 31 KEY STAKEHOLDERS IN PRODUCT BUYING PROCESS 83
FIGURE 32 KEY BUYING CRITERIA FOR PRODUCTS 84
FIGURE 33 NORTH AMERICA: CAR T-CELL THERAPY MARKET SNAPSHOT 148
FIGURE 34 ASIA PACIFIC: CAR T-CELL THERAPY MARKET SNAPSHOT 175
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN CAR T-CELL
THERAPY MARKET (2021–2023) 207
FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CAR T-CELL
THERAPY MARKET (2023) 208
FIGURE 37 RANKING OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET, 2023 209
FIGURE 38 CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 210
FIGURE 39 CAR T-CELL MARKET: COMPANY FOOTPRINT 211
FIGURE 40 CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 214
FIGURE 41 EV/EBITDA OF KEY VENDORS 216
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 216
FIGURE 43 CAR T-CELL THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 217
FIGURE 44 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023) 222
FIGURE 45 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023) 227
FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2023) 233
FIGURE 47 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2023) 238
FIGURE 48 JW (CAYMAN) THERAPEUTICS CO. LTD.: COMPANY SNAPSHOT (2023) 240
